Gut microbiome in Y-T2D: metformin vs. metformin+liraglutide
48 stool samples from African American adolescents with type 2 diabetes in a 3-month trial comparing metformin alone versus metformin+liraglutide, examining gut microbiome and metabolite changes linked to glycemia. machine-written summary
48 samples · 48 runs · US · Adult · 2025 · 1.40 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 288 sample values (collection date, country, latitude, location locality, location region, longitude) |
| ○ Abstract / description | read; no usable statement |
| ✓ Full text | 144 sample values (health condition, health condition detail, location site) · PMC12482426 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention — arms not resolved
Non-antibiotic pharmaceutical given as the study intervention (metformin design randomized_controlled_trial · population type2_diabetes · Randomized to metformin alone vs metformin+liraglutide for 3 months
“randomized to Met ( n = 14) or Met+Lira ( n =” — abstract:41020378 (study level; per-sample arms are in the intervention column below)
longitudinal — not resolved
Schedule stated by the source: “stool at baseline (Visit 2) and after 12 weeks (Visit 5)” (time origin: baseline); stated follow-up 3 mo.
Genera, mean relative abundance over 39 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 48 | 100% | ||||
| country | 48 | 100% | 48 | |||
| health_condition | 48 | 100% | 48 | |||
| subject_id | 0 | 0% | ||||
| collection_date | 48 | 100% | 48 | |||
| detailed_location | 48 | 100% | ||||
| health_condition_detail | 48 | 100% | 48 | |||
| latitude | 48 | 100% | 48 | |||
| location_locality | 48 | 100% | 48 | |||
| location_region | 48 | 100% | 48 | |||
| location_site | 48 | 100% | 48 | |||
| longitude | 48 | 100% | 48 |
- Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study. 2025 PMID 41020378 PMC12482426 own_data
Archive description
We performed a planned secondary analysis of stool samples collected from a 3-month clinical trial involving African American youth with type 2 diabetes (Y-T2D). Participants were randomly assigned to receive either metformin alone or a combination of metformin and liraglutide. The goal of this analysis was to (1) compare the gut microbiome and metabolite profiles between the two treatment groups, and (2) explore how changes in gut bacteria were related to blood sugar metabolism and metabolite levels before and after treatment. Stool samples were collected at the beginning and end of the 3-month intervention. These samples were analyzed using whole genome shotgun sequencing with the Illumina HiSeq 1000 platform, and microbial composition was assessed using metagenomic phylogenetic analysis.
How this project entered the registry
Classified as human gut / stool / blood / tissue / internal fluids shotgun DNA metagenome of adolescent and adult by deterministic_prior with confidence 0.90. Assay shotgun_dna.
- host external_curation.infant_catalog · “infant triage reason_code age_adult_only”
- body site study.title · “Targeting the Gut Microbiome in Youth-Onset”
- body site study.description · “secondary analysis of stool samples collected from”
- body site study.description · “were related to blood sugar metabolism and”
- life stage study.title · “Gut Microbiome in Youth -Onset Type 2”
- life stage study.description · “involving African American youth with type 2”
- life stage external_curation.infant_catalog · “infant triage reason_code age_adult_only”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN49567580 | collection_date | 2022-10-15 | R1 | 0.90 | biosample.attribute:collection_date | 2022-10-15 |
| SAMN49567580 | country | US | R1 | 0.90 | sample.attr.geo_loc_name | USA: Bethesda |
| SAMN49567580 | health_condition | type2_diabetes | R3 | 0.70 | paper.fulltext.methods | diagnosed with Y-T2D by the American Diabetes Association criteria |
| SAMN49567580 | health_condition_detail | Youth-onset type 2 diabetes (Y-T2D) | R3 | 0.70 | paper.fulltext.methods | diagnosed with Y-T2D by the American Diabetes Association criteria |
| SAMN49567580 | latitude | 38.9800 | R1 | 0.90 | biosample.attribute:lat_lon | 38.98 N 77.09 W |
| SAMN49567580 | location_locality | Bethesda | R1 | 0.85 | biosample.attribute:geo_loc_name | USA: Bethesda |
| SAMN49567580 | location_region | Maryland | R1 | 0.60 | biosample.attribute:lat_lon | 38.98 N 77.09 W |
| SAMN49567580 | location_site | NIH Clinical Center | R3 | 0.70 | paper.fulltext.methods | Metabolic Clinical Research Unit at the NIH Clinical Center |
| SAMN49567580 | longitude | -77.0900 | R1 | 0.90 | biosample.attribute:lat_lon | 38.98 N 77.09 W |
Sequencing
48 runs over 48 samples · mean 1.48 Gbp per run (median 1.40 Gbp, total 71.13 Gbp; 48 runs with a base count) · layout PAIRED 48 · platform ILLUMINA 48 · models NextSeq 1000 (48) · 81% of runs with a Sandpiper profile · first public 2025-12-03 – 2025-12-21
Authors (14)
Glaros SB first · Mishra SP · Jain S · Davis FS · Gabel SA · Mueller GA · Jarmusch AK · Mabundo L · Courville AB · Walter MF · Walter PJ · Overdahl KE · Yadav H · Chung ST last
Downloads
PRJNA1281554.csv.gz (2.1 KB) · parquet (72.0 KB) — all 48 samples, every field with route and confidence · PRJNA1281554_determinations.csv.gz (3.2 KB) — 432 evidence rows